By
- Publisher: Springer
- Number Of Pages: 854
- Publication Date: 2005-06-14
- Sales Rank: 760764
- ISBN / ASIN: 0387229493
- EAN: 9780387229492
- Binding: Hardcover
- Manufacturer: Springer
- Studio: Springer
- Average Rating:
- Total Reviews:
Book Description:
Malignant mesothelioma is a rare form of cancer, in which the cancer cells are found in the sac lining the chest (pleura) or abdomen (peritoneum). This lethal disease is associated with asbestos and has vast economic and legal implications. As the disease takes approximately twenty years to manifest itself in humans, a wave of diagnoses is expected in the near future. In the United States alone, an estimated 3,500 - 4,000 patients are diagnosed with mesothelioma annually, and it is estimated that over the next 35 years, more than 250,000 people in Western Europe will be diagnosed with the disease. Malignant Mesothelioma, edited by internationally recognized experts in the field, is a comprehensive text that relates science, pathology, clinical aspects and therapy for mesothelioma under one cover. The book integrates the newest research and advances in its discussions of the disease, covering such topics as carcinogenesis, epidemiology, benchwork, endoscopy, multimodality approaches and treatment. It includes discussions on novel approaches to mesothelioma, such as gene therapy, vaccination strategies and immunotherapy, as well as discussions on the legal and economic aspects of the disease. Over 200 illustrations round out the text. An invaluable reference for the medical oncologist, thoracic surgeon, radiation oncologist, pulmonologist, and benchworker interested in the disease.
Table of Contents
Preface
Contents
- Part One Carcinogenesis
- Part Two Molecular Genetics
- Part Three Epidemiology
- Part Four Clinical Presentation
- Part Five Imaging and Endoscopy
- Part Six Pathology
- Part Seven Treatment
- Part Eight Multimodality Approaches
- Part Nine Novel Treatment Strategies
- Part Ten Economic Implications
Contributors
Part One Carcinogenesis
- 1 The History of Mesothelioma
- Early Discovery, 1767 to 1900
- Histologic Controversy, 1900 to 1942
- De.nition and Suspicion, 1943 to 1960
- Association and Causation, 1960 to 1973
- The Doubters and the Role of Other Forms of Asbestos
- The Role of Amosite and Chrysotile
- References
- 2 Asbestos-Induced Mesothelioma
- Properties of Asbestos Fibers
- Epidemiology of Asbestos-Induced Mesotheliomas
- Properties of Asbestos Associated with Carcinogenic Potential
- Role of Reactive Oxygen and Nitrogen Species (ROS/RNS) in Asbestos Bioreactivity
- Cytogenetic Changes by Asbestos Fibers in Mesothelial Cells and Mesotheliomas
- Cell Signaling Pathways, Growth Factors, and Early Response Proto-Oncogenes
- Effects of Asbestos on Extracellular Matrix
- Conclusion
- References
- 3 SV40-Mediated Oncogenesis
- SV40 Genomic Organization, Gene Transcription, and Cycle of Infection
- Susceptibility to SV40 Infection and SV40-Mediated Transformation
- The SV40 Oncoproteins
- SV40 and Apoptosis
- SV40 Transformation of Human Cells
- SV40 and Malignant Mesothelioma
- Interaction of SV40 with Human Mesothelial Cells in Vitro
- Crossing the Species Boundaries: SV40, a Human Virus?
- Conclusion
- Acknowledgments
- References
- 4 Mesothelioma Carcinogenesis: In Vivo Models
- In Vivo Models of Mesothelioma, Their Purposes, and Roles
- Intrapleural Administration
- Intraperitoneal Administration
- Inhalation
- Intratracheal Instillation
- Ingestion
- Combined Exposures
- Mechanisms and Pathways
- Conclusion
- References
- 5 Mesothelial and Mesothelioma Cell Lines
- Primary Mesothelial Cell Lines
- In Vitro Transformation of Mesothelial Cells
- Malignant Mesothelioma Cell Lines
- Acknowledgment
- References
Part Two Molecular Genetics
- 6 Cytogenetics of Malignant Mesothelioma
- Cytogenetic Assessment of Malignant Mesotheliomas
- Deletion Mapping of Recurrent Chromosomal Losses
- Conclusion
- References
- 7 Growth Factors and Malignant Mesothelioma
- Epidermal Growth Factor and Its Related Molecules
- Transforming Growth Factor-b
- Tumor Necrosis Factor-a
- Platelet-Derived Growth Factors AA, AB, and BB
- Insulin-Like Growth Factors
- Vascular Endothelial Growth Factor
- Fibroblast Growth Factors 1 and 2
- Hepatocyte Growth Factor
- References
- 8 Oncogenes and Tumor Suppressor Genes in Malignant Mesothelioma
- Loss of Function from Cyclin-Dependent Kinase Inhibitors at the 9p21 Locus in Mesothelioma
- Additional Abnormalities of Cyclin-Dependent Kinase Inhibitors in Mesothelioma
- Mutations in the NF2 Gene Are a Common Feature of Mesothelioma
- Alterations of p53 Appear Infrequently in Malignant Mesothelioma
- Apoptosis-Mediating Gene Defects in Mesothelioma
- Epigenetic Inactivation of RASSF1A Occurs in Mesothelioma and After Simian Virus 40 Infection in Mesothelial Cells
- Dominant-Negative WT1 Gene Abnormalities Are Detected in Mesothelioma
- Relationship to Simian Virus 40
- Conclusion
- References
- 9 Angiogenesis and Mesothelioma
- Role of Vascular Endothelial Growth Factor in Malignant Mesothelioma Cell Growth and Progression
- Regulation of Vascular Endothelial Growth Factor Expression by Potential Transforming Factors in Malignant Mesothelioma
- Antiangiogenic Agents as Therapeutic Tools for Malignant Mesothelioma
- Acknowledgments
- References
- 10 Immune Status and Mesothelioma
- Innate Immunity Against Mesothelioma Cells
- Asbestos Exposure and Innate Immunity
- Tumor-In.ltrating Lymphocytes (TIL) in Mesothelioma
- Adaptive Immunity Against Mesothelioma
- Oxidant-Mediated Immunosuppression and Mesothelioma
- Transforming Growth Factor-b–Mediated Immunosuppression and Mesothelioma
- Conclusion
- Acknowledgments
- References
- 11 Extracellular Matrix and Mesothelioma: Some Clues to the Invasive Behavior of Mesothelioma
- Extracellular Matrix
- Basement Membrane and Stroma Composition
- Basement Membrane and Stroma in Normal Mesothelium and Mesotheliomas
- Conclusion
- Acknowledgments
- References
- 12 Genomics and Proteomics in Mesothelioma
- Genomics in Cancer Research
- Proteomics in Cancer Research
- Technologies Involved in Expression Proteomics
- Future of Genomics and Proteomics in Mesothelioma
- References
Part Three Epidemiology
- 13 Asbestos Mineralogy and Health Effects
- Mineralogy of Asbestos Group Minerals
- Identification of Asbestos
- Asbestos Materials and Their Properties
- Alternative Products
- Asbestos Exposures
- Occupational and Environmental Health Hazards Related to Asbestos Exposure
- Asbestos and Mesothelioma
- Mechanisms of the Potentially Hazardous Minerals
- Conclusion
- Acknowledgment
- References
- 14 Molecular Epidemiology of Mesothelioma
- Biomarkers
- Metabolic Susceptibility Markers
- DNA Repair Markers
- Tumor Suppressor Genes
- Oncogenes
- Growth Factors
- References
- 15 Malignant Mesothelioma and Erionite
- Brief History of the Region
- Zeolite-Group Minerals
- Mineralogy of Erionite
- De.nition of Erionite Series
- Geologic and Medical Studies of the Region
- Mesothelioma and Asbestos
- Mesothelioma and Erionite
- Zeolite Toxicity Experiments Using Animals
- Mortality Studies
- Genetic Studies Suggest Predisposition to Erionite Carcinogenesis
- Erionite in Turkey
- Conclusion
- References
- 16 Determination of Asbestos Exposure by Pathology and Clinical History
- Clinical History
- Clinical and Radiologic Markers of Exposure
- Histopathologic Evaluation of Cases
- References
- 17 Mesothelioma and Asbestos Exposure
- Historical Background
- The Link with Asbestos
- Early Case-Control Studies
- Occupational Risk
- Other Causes
- Lung Burden Analyses
- The Tremolite Factor
- n = 406) (reference: US white males) (90)
- Synthesis
- Conclusion
- References
- 18 From Monkey to Man: The Epidemiologic Evidence of an Association Between Simian Virus 40 and Malignancy
- Epidemiologic Investigations
- Summary
- References
- 19 Causes and Prevention of Technical Artifacts When Studying Simian Virus 40 (SV40) in Human Mesotheliomas
- Introduction to the SV40 Genome, SV40 Early Proteins Large Tumor (T)-Antigen and Small Tumor (t)-Antigen
- Detection of SV40 DNA in Tissues and Cells by Polymerase Chain Reaction
- Speci.city of PCR for SV40 Detection
- Reproducibility of the PCR Reaction
- Immunohistochemical Demonstration of SV40
- References
- 20 Molecular Detection of Siman Virus 40 in Human Mesothelioma
- Rationale for SV40 Detection in Human Mesothelioma
- Reliability of SV40 Detection
- Reliability of DNA Extraction
- Optimum Polymerase Chain Reaction Conditions
- Optimum Polymerase Chain Reaction Product Detection
- Recommended Method
- Critique of Molecular Detection of SV40
- Conclusion and Future Work
- Appendix
- Fresh/Frozen Tissue
- Paraffin-Embedded Tissue
- References
- 21 Malignant Mesothelioma Following Radiation
- Animal Models of Radiation-Induced Mesothelioma
- Carcinogenic Effect of Radiation in Humans
- Radiation-Induced Sarcomas
- Thorotrast-Related Mesotheliomas
- Case Reports of Radiation-Associated Mesotheliomas
- Mesotheliomas May Be Underdiagnosed and Misdiagnosed
- Population-Based Studies of Radiation-Associated Mesotheliomas
- Conclusion
- References
- 22 Genetics and Human Mesothelioma
- Acknowledgments
- References
Part Four Clinical Presentation
- 23 Clinicians’ Approach to Mesothelioma
- Diagnostic Approach
- Prognosis
- Clinical Decisions
- Pathology Considerations for the Clinician
- Counseling Patients at Risk
- Assessment of Individual Risk
- Selecting Treatment
- Counseling Patients about Legal Aspects
- Primary and Secondary Prevention Programs
- References
- 24 Clinical Presentation and Natural History of Mesothelioma: Pleural and Pericardial
- Malignant Pleural Mesothelioma
- Demographics and General Characteristics
- Clinical Symptoms and Diagnosis
- Malignant Pericardial Mesothelioma
- Addendum
- References
- 25 Clinical Presentation and Natural History of Mesothelioma: Abdominal
- Epidemiology and Etiology
- Pathology
- Differential Diagnosis
- Clinical Presentation
- Pathophysiology
- Treatment
- Survival
- Conclusion
- Acknowledgments
- References
- 26 Staging of Mesothelioma
- History of the Staging of Mesothelioma
- The AJCC Staging System for Malignant Pleural Mesothelioma
- Clinical Staging in Mesothelioma
- Summary
- References
- 27 Prognostic Factors in Mesothelioma
- Diagnosis of Malignant Mesothelioma
- Natural History of Malignant Mesothelioma
- Clinical Prognostic Factors for Malignant Mesothelioma
- The Cancer and Leukemia Group B (CALGB) Prognostic Scoring System
- The European Organization for Research and Treatment of Cancer (EORTC) Prognostic Scoring System
- Validation of the CALGB and EORTC Prognostic Models by Other Groups
- Novel Molecular Predictors of Prognosis
- Conclusion
- References
Part Five Imaging and Endoscopy
- 28 Radiologic Assessment of Mesothelioma
- Imaging Modalities
- Tumor Measurement
- References
- 29 Endoscopic Imaging
- Thoracoscopy
- Laparoscopy
- References
Part Six Pathology
- 30 Benign Mesotheliomas, Mesothelial Proliferations, and Their Possible Association with Asbestos Exposure
- Malignant Mesothelioma In Situ
- Epithelial Benign Mesotheliomas and Mesothelial Proliferation
- Well-Differentiated Papillary Mesothelioma
- Adenomatoid Tumor
- Mesothelioma of the Atrioventricular Node
- Peritoneal Multicystic Mesothelioma
- Mesenchymal Benign Mesothelial Tumors and Mesothelial Proliferations
- Possible Relation of Benign Mesotheliomas and Mesothelial Proliferations to Asbestos Exposure
- References
- 31 Cytology of Malignant Mesothelioma
- References
- 32 Immunohistochemistry
- Immunohistochemistry and Epithelial Malignant Mesothelioma vs. Metastatic Carcinoma
- Immunohistochemistry and Sarcomatoid Mesothelioma vs. Spindle Cell Malignancies
- Immunohistochemistry and Benign vs. Malignant Mesothelium
- References
- 33 Malignant Mesothelioma Electron Microscopy
- Epithelial Mesothelioma
- Sarcomatoid Mesothelioma
- Mixed (Biphasic-Transitional) Mesothelioma
- Technical Considerations
- Viral Pathogenesis
- References
- 34 Rare Variants of Mesothelioma
- Multicystic (Benign) Peritoneal Mesothelioma (Benign Cystic Mesothelioma, Multilocular Peritoneal Inclusion Cyst)
- Well-Differentiated Papillary Mesothelioma of Peritoneum
- Deciduoid Mesothelioma
- Desmoplastic Malignant Mesothelioma
- Lymphohistiocytoid Mesothelioma
- Small Cell Mesothelioma
- References
- 35 Differentiating Sarcomas from Mesotheliomas
- Sarcoma Versus Malignant Mesothelioma: General Differential Diagnostic Considerations
- Synovial Sarcoma Versus Malignant Mesothelioma
- Epithelioid Hemangioendothelioma/Angiosarcoma Versus Malignant Mesothelioma
- Solitary Fibrous Tumor Versus Malignant Mesothelioma
- References
- 36 Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma
- Clinical History
- Gross Pathology
- Histopathology
- Mucin
- Immunohistochemistry
- Electron Microscopy
- Molecular Studies
- Conclusion
- References
- 37 Pitfalls in the Diagnosis of Malignant Mesothelioma
- Epithelial Mesothelioma Versus Mesothelial Hyperplasia
- Organizing Fibrous Pleuritis Versus Sarcomatoid or Desmoplastic Mesothelioma
- Benign Processes Mimicking Mesothelioma
- Metastatic or Primary Malignancies of the Pleura Mimicking Malignant Mesothelioma
- Mesotheliomas as Mimickers of Other Diseases
- Rare Variants of Mesothelioma with Indeterminate Behavior
- Diagnostic Pitfalls in the Diagnosis of Metastatic Mesothelioma
- References
Part Seven Treatment
- 38 Management of Benign Variants of Mesothelioma
- Non-neoplastic Lesions of the Pleura
- Solitary Fibrous Tumor of the Pleura
- Other Less Common Tumors of the Pleura
- Summary
- References
- 39 First-Line Chemotherapy for Malignant Pleural Mesothelioma
- The Impact of Systemic Chemotherapy
- Evaluating the Impact of Chemotherapy
- Single-Agent Chemotherapy
- Combination Chemotherapy
- Conclusions and Future Directions
- Summary
- References
- 40 Second-Line Chemotherapy
- Review of the Literature
- Future Directions
- Conclusion
- References
- 41 Treatment of Mesothelioma with Radiotherapy
- General Principles of Radiation Therapy
- Curative Radiation Therapy as a Single Modality
- Combined Chemotherapy and De.nitive Radiotherapy
- Combined Surgical Resection and De.nitive Radiotherapy
- Prevention of Scar Recurrences
- Palliation
- Peritoneal Mesothelioma
- Conclusion
- References
Part Eight Multimodality Approaches
- 42 Intrapleural Chemotherapy with and Without Surgery in Malignant Pleural Mesothelioma (MPM)
- Intrapleural Chemotherapy
- Intrapleural Chemotherapy with Surgical Debulking
- Hyperthermic Intrapleural Chemotherapy
- Liposome-Entrapped Platinum Derivative
- Conclusion and Future Directions
- References
- 43 Management of Pleural Effusions in Mesothelioma
- Indications for Palliation
- Methods of Palliation
- Chemical Pleurodesis
- Mechanical Pleurodesis
- Tube Thoracostomy
- Pleurx Catheter Drainage
- Pleuroperitoneal Shunt
- Intracavitary Chemotherapy and Hyperthermia
- Radiotherapy
- Immunotherapy
- Special Considerations
- Summary
- References
- 44 Preoperative Chemotherapy and Surgery
- The University of Washington Experience
- Other Experiences Published
- Conclusion
- References
- 45 Photodynamic Therapy for Pleural Mesothelioma
- Photodynamic Therapy for Mesothelioma
- Clinical Studies
- Conclusion
- Summary
- References
- 46 Surgery and Postoperative Radiotherapy
- Palliative Radiotherapy
- Prophylactic Radiotherapy
- Surgical Resection Plus Radiotherapy
- Surgery
- High-Dose Hemithoracic Radiation Treatment Plan
- Summary
- References
- 47 The Development of the Brigham and Women’s Multimodality Treatment Plan for Malignant Pleural Mesothelioma: A Model for Impr
- Historical Context
- Frequency of Disease in New England
- The 1980s: Diagnosis and Recognition of the Disease
- The Early 1990s: Development of Multidisciplinary Expertise
- Late 1990s: Development of Intraoperative Bicavitary Heated Chemotherapy
- The New Millennium and New Frontiers
- References
- 48 Peritoneal Mesothelioma: The Columbia Experience
- Peritoneal Mesothelioma Background
- Rationale for Local/Regional Therapy: Debulking, Radiation, and Intraperitoneal Chemotherapy
- Novel Therapies for Peritoneal Mesothelioma
- Multimodality Treatment of Peritoneal Mesothelioma Using Cytoreductive Surgery and Intraperitoneal Chemotherapy
- The Columbia University Experience
- Cytoreduction
- Normothermic Intraperitoneal Chemotherapy
- Second-Look Surgery and Hyperthermic
- Intraperitoneal Chemotherapy
- References
- 49 Surgery, Hyperthermic Chemoperfusion, and Postoperative Chemotherapy: The National Cancer Institute and Washington Hospital C
- Presentation
- Combined Therapy at the NCI and WCI
- Advantages and Disadvantages of Combined Therapy
- Technique of Continuous Hyperthermic Peritoneal Perfusion
- NCI Results
- WCI Results
- Morbidity and Mortality of Combined Therapy
- Summary
- References
- 50 Pericardial and Tunica Vaginalis Mesothelioma
- References
Part Nine Novel Treatment Strategies
- 51 New Target Therapies for Malignant Mesothelioma
- Targeting the Epidermal Growth Factor Receptor Pathway
- Targeting the Platelet-Derived Growth Factor Receptor Pathway
- Targeting Vascular Endothelial Growth Factor Signaling Pathway
- Targeting the Hepatocyte Growth Factor Signaling Pathway
- Targeting the Downstream Signaling Pathway
- Targeting the Proteasome/Ubiquitin Pathway
- References
- 52 Gene Therapy for Malignant Pleural Mesothelioma
- Gene Therapy: Principles and Vectors
- “Suicide” Gene Therapy
- tk Suicide Gene Therapy
- tk Gene Therapy
- Suicide Gene Vaccines
- Cytokine Gene Therapy for Mesothelioma
- The Future of Genetic Immunotherapy for Mesothelioma
- Induction of Apoptosis
- SV40: Is There a Role in Therapy for Mesothelioma?
- Replicating Viruses
- Summary
- References
- 53 Immunotherapeutic Approaches and Vaccination Strategies
- The Immune Response to a Solid Tumor
- Immunotherapy in Malignant Mesothelioma
- Conclusions and Future Directions
- Acknowledgments
- References
Part Ten Economic Implications
- 54 Economic Aspects of Mesothelioma
- Relationship of Mesothelioma to Asbestos in General
- Economic Value of Asbestos Litigation
- History of Asbestos Litigation
- Sources of Compensation
- Measures of Damages
- Volume of Cases
- Transactional Costs
- Judicial Management Techniques
- Medical Expert Witnesses
- Punitive Damages
- Abatement of Asbestos in Buildings
- The Creation of Industries
- The Destruction of Industries
- The New Wave of Asbestos Litigation
- Conclusion
- References
Index
DOWNLOAD THIS BOOK
